Wednesday , 12 December 2018
Breaking News
Aurobindo Pharma expecting first biosimilar approval in US in 12-18 months

Aurobindo Pharma expecting first biosimilar approval in US in 12-18 months

Aurobindo Pharma is expecting to receive an approval for its first biosimilar product in the US in the next 12-18 months, while in Europe, the company hopes a green signal by 2022.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Loading...

Leave a Reply

Your email address will not be published. Required fields are marked *

*